GO
Loading...

Enter multiple symbols separated by commas

Novartis AG

More

  • NEW YORK, May 7- New therapies that clinical data show can eliminate blood cancers such as leukemia and lymphoma in 40 percent to 90 percent of patients may have to be genetically modified to include a switch that shields healthy cells from attack. The therapies could generate tens of billions of dollars in annual sales for drugmakers including Kite Pharma and...

  • NEW YORK, May 6- Drugmakers are building safety "switches" that can be used to turn off powerful cancer therapies known as CAR T cells when they cause life-threatening inflammation or attack healthy tissue. *Bellicum Pharmaceuticals Inc has developed a "switch" by genetically programming a CAR T cell to kill itself when exposed to a drug called rimiducid,...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • GSK CEO: Why we're betting on drug volume, not price Wednesday, 6 May 2015 | 12:21 PM ET

    GlaxoSmithKline laid out growth targets for biggest businesses on Wednesday, hoping to convince investors that it would return to long-term growth.

  • It also scaled back plans to return 4 billion pounds of cash flowing from a $20 billion- plus asset swap with Novartis to investors, opting instead to pay a 1 billion special dividend. Chief Executive Andrew Witty is under pressure to demonstrate that the Novartis deal can revive GSK's fortunes by focusing it on consumer health and vaccines, following a slide in...

  • Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion- plus asset swap with Novartis can revive GSK's fortunes, following a damaging slide in lung drug sales and a major corruption scandal in China. In a bid to protect its dividend, GSK scaled back plans to return 4 billion pounds of cash flowing from the Novartis transaction to...

  • LONDON, May 6- GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth. Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion- plus asset swap with Novartis can revive GSK's...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • NEW YORK, May 1- U.S. authorities said on Friday that a unit of Express Scripts Holding Co will pay $60 million to resolve claims that it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements. Specialty pharmacy Accredo Health Group Inc has agreed to pay $45.1 million to the federal government...

  • NEW YORK, May 1- A unit of pharmacy benefits manager Express Scripts Holding Co will pay $45 million to resolve U.S. claims it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements. The settlement with specialty pharmacy Accredo Health Group Inc was disclosed in court papers filed Thursday in...

  • *Cash return was planned after Novartis asset swap deal. Instead, Britain's biggest drugmaker could use cash flowing in from its far-reaching asset swap deal with Novartis to support its dividend, according to analysts at Goldman Sachs and Berenberg Bank. GSK said last year it intended to return 4 billion pounds to shareholders in 2015 through a so-called B...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote "all necessary resources" to its $40 billion- plus bid for rival Mylan Inc..

  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries, which is seeking to acquire rival Mylan Inc for over $40 billion, raised its full-year earnings outlook after posting a bigger-than-expected increase in first-quarter profit.

  • As sensors shrink, watch as 'wearables' disappear Wednesday, 29 Apr 2015 | 5:00 PM ET

    "In five years, when we look back, everything we see will absolutely be classified as toys, as the first very basic steps of getting this right," says Nikolaj Hviid, the man behind smart earbuds called the Dash. Developed by Munich- based Bragi GmbH, the Dash is a wireless in-ear headphone that looks like a discreet hearing aid. Nick Hunn, a consultant who lays claim to the...

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • DETROIT, April 24- General Motors Co Chief Executive Officer Mary Barra, who last year became the first woman to lead a major U.S. automaker, received $16.2 million in 2014 compensation, up 78 percent from her predecessor's total the previous year. She received $4.55 million in salary and other liquid compensation for 2014, GM said in a proxy filed on Friday with...

  • The 10 global companies that get diversity: Study Friday, 24 Apr 2015 | 11:03 AM ET

    These 10 companies lead the way when it comes to diversity as a cultural and business aim, according to an annual ranking from DiversityInc.

  • European shares end mostly lower, Ericsson tanks Thursday, 23 Apr 2015 | 11:30 AM ET
    Paris cafe with Eiffel Tower in background

    Euro zone equities finished largely lower on Thursday, as investors digested earnings news and economic data.